

Harnessing the Adimab platform for the discovery of TTX-080: A clinical HLA-G antibody

Bianka Prinz*, Joseph Warfield*, Paul Widboom*, Ross Connor*, Kelsie Prosser*, Courtney Beers††, Vanessa Soros††, Doug Hodges††, Eric Krauland*, William Roach*

ADIMAB

*Adimab LLC, 7 Lucent Drive, Lebanon NH 03766

††Tizona Therapeutics, 4000 Shoreline Court, South San Francisco CA 94080

BACKGROUND

Adimab's discovery and optimization platform excels in identifying diverse, highly specific, and developable antibody panels. With over 15 years of expertise, Adimab's technology has been successfully leveraged on more than 600 therapeutic antibody campaigns with over 130 partners.

140+ Pharma/Biotech Partners **650+** Therapeutic Programs **80+** Clinical Advancements **6** Approved Products

DISCOVERY AND OPTIMIZATION OF CLINICAL MOLECULE TTX-080




Target nomination: HLA-G background

Tizona Therapeutics' target product profile

1. Specificity for HLA-G: 90% sequence ID to class I MHC
2. Blocks ILT2 and ILT4
3. Sub-nM affinity to HLA-G
4. Sub-nM IC50 in immune cell assays

	193	194	195	196	197	198
HLA-G	P	V	F	D	Y	E
HLA-A1	P	I	S	D	H	E
HLA-A2	A	V	S	D	H	E



HLA-G differs by only two residues in the ILT2/4 binding pocket from other class I MHCs

Adimab synthetic and immune sources of diversity

Full-length IgG and HCAb libraries expressed in engineered Adimab yeast strain




Figure 2: IgG optimization and clinical lead nomination






Figure 1: IgG discovery and Tizona evaluation


a) Enrichment of HLA-G specific binding population: 34 HLA-G specific IgGs delivered




b) 26 unique V_H/V_L germline combinations



c) 32 unique CDR-H3 delivered



d) ILT2 blockers identified in NK cell assay*



e) Specificity confirmed against 94 HLAs*
5 IgGs nominated for optimization





Figure 3: TTX-080 achieves target product profile; clinical trials initiated*



Acknowledgments:

We thank our partners at Tizona for functional and clinical data. All members of the Adimab scientific and engineering teams contributed to this program.

Contact Adimab

If you are interested in partnering with Adimab, please reach out to our Business Development department at bd@adimab.com.

The QR code on the right links to Adimab posters and other resources.

